Obchod OncoCyte Corporation - OCX CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Podmienky obchodovania
| Rozpätie | 0.0025 | ||||||||
|
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.025457% | ||||||||
|
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | 0.003235% | ||||||||
| Nočný poplatok | 21:00 (UTC) | ||||||||
| Minimálne množstvo na obchodovanie | 1 | ||||||||
| Mena | USD | ||||||||
| Marža | 20% | ||||||||
| Burza cenných papierov | United States of America | ||||||||
| Provízia pri predaji | 0% |
*Information provided by Capital.com
OncoCyte Corp ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Kľúčové štatistiky
| Predchádzajúce Zavrieť* | 0.2136 |
| Otvoriť* | 0.2136 |
| 1-ročná zmena* | -77.52% |
| Denný rozsah* | 0.2023 - 0.2176 |
| Rozsah 52 týždňov | 0.20-1.35 |
| Priemerný objem (10 dní) | 334.83K |
| Priemerný objem (3 mesiace) | 11.21M |
| Trhová kapitalizácia | 35.44M |
| Pomer P/E | -100.00K |
| Zdieľa mimoriadne | 164.82M |
| Výnosy | 875.00K |
| EPS | -0.09 |
| Dividenda (udalosť %) | N/A |
| Beta | 1.58 |
| Ďalší dátum zárobku | Aug 8, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 0.2142 | 0.0006 | 0.28% | 0.2136 | 0.2189 | 0.2023 |
| May 25, 2023 | 0.2136 | -0.0106 | -4.73% | 0.2242 | 0.2242 | 0.2052 |
| May 24, 2023 | 0.2187 | 0.0094 | 4.49% | 0.2093 | 0.2232 | 0.2056 |
| May 23, 2023 | 0.2172 | -0.0120 | -5.24% | 0.2292 | 0.2373 | 0.2172 |
| May 22, 2023 | 0.2323 | 0.0008 | 0.35% | 0.2315 | 0.2390 | 0.2293 |
| May 19, 2023 | 0.2282 | -0.0110 | -4.60% | 0.2392 | 0.2492 | 0.2193 |
| May 18, 2023 | 0.2535 | 0.0044 | 1.77% | 0.2491 | 0.2542 | 0.2463 |
| May 17, 2023 | 0.2563 | 0.0122 | 5.00% | 0.2441 | 0.2614 | 0.2441 |
| May 16, 2023 | 0.2586 | -0.0005 | -0.19% | 0.2591 | 0.2591 | 0.2531 |
| May 15, 2023 | 0.2651 | 0.0060 | 2.32% | 0.2591 | 0.2691 | 0.2521 |
| May 12, 2023 | 0.2507 | -0.0185 | -6.87% | 0.2692 | 0.2699 | 0.2473 |
| May 11, 2023 | 0.2723 | -0.0038 | -1.38% | 0.2761 | 0.2837 | 0.2659 |
| May 10, 2023 | 0.2659 | 0.0068 | 2.62% | 0.2591 | 0.2732 | 0.2591 |
| May 9, 2023 | 0.2623 | 0.0019 | 0.73% | 0.2604 | 0.2642 | 0.2591 |
| May 8, 2023 | 0.2672 | 0.0080 | 3.09% | 0.2592 | 0.2691 | 0.2591 |
| May 5, 2023 | 0.2603 | 0.0001 | 0.04% | 0.2602 | 0.2647 | 0.2466 |
| May 4, 2023 | 0.2674 | 0.0083 | 3.20% | 0.2591 | 0.2698 | 0.2591 |
| May 3, 2023 | 0.2531 | -0.0160 | -5.95% | 0.2691 | 0.2698 | 0.2491 |
| May 2, 2023 | 0.2607 | -0.0084 | -3.12% | 0.2691 | 0.2691 | 0.2591 |
| May 1, 2023 | 0.2741 | 0.0060 | 2.24% | 0.2681 | 0.3075 | 0.2681 |
OncoCyte Corporation Events
| Čas (UTC) (UTC) | Krajina | Udalosť |
|---|---|---|
| Friday, June 23, 2023 | ||
| Čas (UTC) (UTC) 17:00 | Krajina US
| Udalosť OncoCyte Corp Annual Shareholders Meeting OncoCyte Corp Annual Shareholders MeetingForecast -Previous - |
| Friday, July 14, 2023 | ||
| Čas (UTC) (UTC) 17:00 | Krajina US
| Udalosť OncoCyte Corp Annual Shareholders Meeting OncoCyte Corp Annual Shareholders MeetingForecast -Previous - |
| Tuesday, August 8, 2023 | ||
| Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q2 2023 OncoCyte Corp Earnings Release Q2 2023 OncoCyte Corp Earnings ReleaseForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q3 2023 OncoCyte Corp Earnings Release Q3 2023 OncoCyte Corp Earnings ReleaseForecast -Previous - |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové príjmy | 0.958 | 2.198 | 1.216 | 0 | 0 |
| Celkové prevádzkové náklady | 18.955 | 54.782 | 30.927 | 22.392 | 15.202 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 21.533 | 20.392 | 23.282 | 15.445 | 8.688 |
| Výskum a vývoj | 6.965 | 4.807 | 9.378 | 6.794 | 6.514 |
| Prevádzkový príjem | -17.997 | -52.584 | -29.711 | -22.392 | -15.202 |
| Úrokový príjem (výdavky), čistý neprevádzkový | -0.548 | -0.25 | -1.502 | -0.031 | -0.643 |
| Čistý príjem pred zdanením | -18.612 | -52.871 | -31.186 | -22.426 | -15.754 |
| Čistý príjem po zdanení | -18.612 | -43.61 | -29.932 | -22.426 | -15.754 |
| Čistý príjem pred extra. Položky | -18.612 | -43.61 | -29.932 | -22.426 | -15.754 |
| Čistý príjem | -72.902 | -64.097 | -29.932 | -22.426 | -15.754 |
| Príjem k dispozícii bežnému Extra. Položky | -19.132 | -43.61 | -29.932 | -22.426 | -15.754 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -73.422 | -64.097 | -29.932 | -22.426 | -15.754 |
| Zriedený čistý príjem | -73.422 | -64.097 | -29.932 | -22.426 | -15.754 |
| Zriedený vážený priemer akcií | 110.8 | 88.92 | 65.478 | 51.296 | 37.85 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.17267 | -0.49044 | -0.45713 | -0.43719 | -0.41622 |
| Zriedený normalizovaný EPS | 0.0095 | -0.48086 | -0.45294 | -0.43421 | -0.41622 |
| Iné, Net | -0.067 | -0.037 | 0.027 | -0.003 | 0.091 |
| Celkom mimoriadne položky | -54.29 | -20.487 | |||
| Nezvyčajné výdavky (príjem) | 20.185 | 1.311 | 0.422 | 0.153 | |
| Výnosy | 0.958 | 2.198 | 1.216 | ||
| Náklady na výnosy, celkom | 0.976 | 0.778 | 1.855 | ||
| Hrubý zisk | -0.018 | 1.42 | -0.639 | ||
| Other Operating Expenses, Total | -31.019 | 27.266 | -4.01 | ||
| Depreciation / Amortization | 0.315 | 0.228 | |||
| Total Adjustments to Net Income | -0.52 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové príjmy | 0.297 | 0.958 | 1.017 | 2.067 | 0.38 |
| Výnosy | 0.297 | 0.958 | 1.017 | 2.067 | 0.38 |
| Náklady na výnosy, celkom | 0.287 | 0.976 | 2.191 | 2.381 | 0.133 |
| Hrubý zisk | 0.01 | -0.018 | -1.174 | -0.314 | 0.247 |
| Celkové prevádzkové náklady | -5.553 | 18.955 | 10.238 | 10.629 | 3.397 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 4.107 | 21.533 | 9.21 | 8.908 | 5.913 |
| Výskum a vývoj | 1.764 | 6.965 | 4.125 | 5.285 | 1.941 |
| Other Operating Expenses, Total | -18.307 | -31.019 | -6.142 | -6.359 | -4.656 |
| Prevádzkový príjem | 5.85 | -17.997 | -9.221 | -8.562 | -3.017 |
| Úrokový príjem (výdavky), čistý neprevádzkový | 0.111 | -0.548 | -0.174 | -0.016 | -0.36 |
| Iné, Net | -0.002 | -0.067 | 0.062 | 0.278 | -0.036 |
| Čistý príjem pred zdanením | 5.959 | -18.612 | -9.333 | -8.3 | -3.413 |
| Čistý príjem po zdanení | 5.959 | -18.612 | -9.333 | -8.3 | -3.413 |
| Čistý príjem pred extra. Položky | 5.959 | -18.612 | -9.333 | -8.3 | -3.413 |
| Čistý príjem | 3.457 | -72.902 | -9.333 | -8.3 | -10.291 |
| Príjem k dispozícii bežnému Extra. Položky | 4.9 | -19.132 | -9.555 | -8.372 | -3.413 |
| Príjem k dispozícii bežnému vr. Extra. Položky | 2.398 | -73.422 | -9.555 | -8.372 | -10.291 |
| Zriedený čistý príjem | 2.398 | -73.422 | -9.555 | -8.372 | -10.291 |
| Zriedený vážený priemer akcií | 119.253 | 110.8 | 118.61 | 113.042 | 92.243 |
| Zriedený EPS s výnimkou mimoriadnych položiek | 0.04109 | -0.17267 | -0.08056 | -0.07406 | -0.037 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Zriedený normalizovaný EPS | 0.09336 | 0.0095 | -0.07585 | -0.07296 | -0.037 |
| Nezvyčajné výdavky (príjem) | 6.233 | 20.185 | 0.558 | 0.125 | 0 |
| Depreciation / Amortization | 0.363 | 0.315 | 0.296 | 0.289 | 0.066 |
| Celkom mimoriadne položky | -2.502 | -54.29 | -6.878 | ||
| Total Adjustments to Net Income | -1.059 | -0.52 | -0.222 | -0.072 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové aktíva | 25.536 | 39.143 | 9.226 | 22.956 | 8.642 |
| Hotovosť a krátkodobé investície | 20.426 | 36.509 | 7.818 | 22.451 | 8.462 |
| Hotovosť a ekvivalenty | 19.993 | 35.605 | 7.143 | 22.072 | 8.034 |
| Krátkodobé investície | 0.433 | 0.904 | 0.675 | 0.379 | 0.428 |
| Prepaid Expenses | 0.977 | 0.693 | 1.205 | 0.505 | 0.18 |
| Other Current Assets, Total | 2.121 | ||||
| Total Assets | 100.091 | 159.563 | 55.419 | 39.859 | 9.518 |
| Property/Plant/Equipment, Total - Net | 10.851 | 8.527 | 6.524 | 3.728 | 0.614 |
| Property/Plant/Equipment, Total - Gross | 15.047 | 11.242 | 7.964 | 4.071 | 1.562 |
| Accumulated Depreciation, Total | -4.196 | -2.715 | -1.44 | -0.343 | -0.948 |
| Intangibles, Net | 61.633 | 91.245 | 15.009 | 0 | |
| Other Long Term Assets, Total | 2.071 | 1.964 | 2.056 | 2.211 | 0.262 |
| Total Current Liabilities | 12.106 | 14.12 | 8.996 | 4.44 | 5.561 |
| Accounts Payable | 1.253 | 2.447 | 0.432 | 0.469 | 0.166 |
| Accrued Expenses | 8.731 | 10.256 | 5.423 | 2.769 | 2.109 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.117 | 1.417 | 2.541 | 1.196 | 1.185 |
| Other Current Liabilities, Total | 2.005 | 0.6 | 0.006 | 2.101 | |
| Total Liabilities | 60.497 | 94.346 | 21.936 | 9.021 | 6.095 |
| Total Long Term Debt | 0 | 0.117 | 1.729 | 1.963 | 0.534 |
| Capital Lease Obligations | 0 | 0.117 | 0.221 | 0.058 | 0.187 |
| Total Equity | 39.594 | 65.217 | 33.483 | 30.838 | 3.423 |
| Preferred Stock - Non Redeemable, Net | 5.302 | 0 | 0 | ||
| Common Stock | 294.929 | 252.954 | 157.16 | 124.583 | 74.742 |
| Retained Earnings (Accumulated Deficit) | -260.676 | -187.774 | -123.677 | -93.745 | -71.319 |
| Other Equity, Total | 0.039 | 0.037 | 0 | ||
| Total Liabilities & Shareholders’ Equity | 100.091 | 159.563 | 55.419 | 39.859 | 9.518 |
| Total Common Shares Outstanding | 118.644 | 92.232 | 69.117 | 57.032 | 40.664 |
| Long Term Debt | 0 | 1.508 | 1.905 | 0.347 | |
| Long Term Investments | 0 | 13.417 | 10.964 | ||
| Other Liabilities, Total | 48.391 | 80.109 | 11.211 | 2.618 | |
| Pohľadávky celkom, netto | 2.012 | 1.637 | 0.203 | ||
| Accounts Receivable - Trade, Net | 2.012 | 1.437 | 0.203 | ||
| Goodwill, Net | 0 | 18.684 | 9.187 | ||
| Total Inventory | 0.304 | ||||
| Total Preferred Shares Outstanding | 0.00001 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové aktíva | 15.648 | 25.536 | 36.636 | 49.368 | 24.623 |
| Hotovosť a krátkodobé investície | 12.356 | 20.426 | 32.472 | 45.415 | 20.986 |
| Hotovosť a ekvivalenty | 11.803 | 19.993 | 32.053 | 44.836 | 20.412 |
| Krátkodobé investície | 0.553 | 0.433 | 0.419 | 0.579 | 0.574 |
| Pohľadávky celkom, netto | 1.901 | 2.012 | 1.99 | 1.802 | 2.122 |
| Accounts Receivable - Trade, Net | 1.901 | 2.012 | 1.99 | 1.802 | 2.122 |
| Prepaid Expenses | 0.97 | 0.977 | 2.174 | 2.151 | 1.515 |
| Total Assets | 82.8 | 100.091 | 157.344 | 171.051 | 146.273 |
| Property/Plant/Equipment, Total - Net | 8.424 | 10.851 | 11.593 | 11.576 | 10.651 |
| Property/Plant/Equipment, Total - Gross | 13.196 | 15.047 | 15.73 | 15.197 | 13.769 |
| Accumulated Depreciation, Total | -4.772 | -4.196 | -4.137 | -3.621 | -3.117 |
| Goodwill, Net | 0 | 18.684 | 18.684 | 18.684 | |
| Intangibles, Net | 56.661 | 61.633 | 88.365 | 89.341 | 90.317 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 2.067 | 2.071 | 2.066 | 2.082 | 1.998 |
| Total Current Liabilities | 9.43 | 12.106 | 12.952 | 14.154 | 13.955 |
| Accounts Payable | 1.395 | 1.253 | 1.826 | 2.465 | 2.584 |
| Accrued Expenses | 7.71 | 8.731 | 11.013 | 11.005 | 10.319 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.089 | 0.117 | 0.113 | 0.684 | 1.052 |
| Other Current Liabilities, Total | 0.236 | 2.005 | |||
| Total Liabilities | 39.335 | 60.497 | 75.411 | 82.954 | 89.306 |
| Total Long Term Debt | 0 | 0 | 0.031 | 0.06 | 0.089 |
| Long Term Debt | |||||
| Capital Lease Obligations | 0 | 0 | 0.031 | 0.06 | 0.089 |
| Other Liabilities, Total | 29.905 | 48.391 | 62.428 | 68.74 | 75.262 |
| Total Equity | 43.465 | 39.594 | 81.933 | 88.097 | 56.967 |
| Common Stock | 295.533 | 294.929 | 292.536 | 289.649 | 254.994 |
| Retained Earnings (Accumulated Deficit) | -257.643 | -260.676 | -215.698 | -206.437 | -198.065 |
| Total Liabilities & Shareholders’ Equity | 82.8 | 100.091 | 157.344 | 171.051 | 146.273 |
| Total Common Shares Outstanding | 119.279 | 118.644 | 118.619 | 118.609 | 92.247 |
| Other Equity, Total | 0.043 | 0.039 | 0.019 | 0.031 | 0.038 |
| Preferred Stock - Non Redeemable, Net | 5.532 | 5.302 | 5.076 | 4.854 | |
| Other Current Assets, Total | 0.421 | 2.121 | |||
| Total Preferred Shares Outstanding | 0.00001 | 0.00001 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čistý príjem/Počiatočná čiara | -72.902 | -64.097 | -29.932 | -22.426 | -15.754 |
| Hotovosť z prevádzkovej činnosti | -45.568 | -35.941 | -25.98 | -19.715 | -11.649 |
| Hotovosť z prevádzkovej činnosti | 1.528 | 0.844 | 0.313 | 0.344 | 0.438 |
| Amortization | 3.692 | 3.361 | 0.081 | 0 | 0.121 |
| Bezhotovostné položky | 24.056 | 35.415 | 4.413 | 3.922 | 2.553 |
| Zmeny pracovného kapitálu | -1.942 | -2.203 | 0.399 | -1.555 | 0.993 |
| Peniaze z investičných činností | -4.34 | -13.961 | -11.748 | -12.415 | -0.031 |
| Kapitálové výdavky | -4.34 | -2.247 | -1.227 | -0.918 | -0.031 |
| Ostatné investičné položky peňažných tokov, celkom | 0 | -11.714 | -10.521 | -11.497 | 0 |
| Hotovosť z finančných činností | 35.806 | 78.364 | 22.799 | 47.868 | 12.114 |
| Financovanie položiek peňažných tokov | -0.483 | -3.065 | -0.132 | -3.288 | -0.355 |
| Vydanie (vyradenie) zásob, netto | 37.718 | 82.963 | 22.236 | 49.793 | 13.65 |
| Vydanie (vyradenie) dlhu, netto | -1.429 | -1.534 | 0.695 | 1.363 | -1.181 |
| Čistá zmena v hotovosti | -14.102 | 28.462 | -14.929 | 15.738 | 0.434 |
| Úroky zaplatené v hotovosti | 0.024 | 0.114 | 0.209 | 0.171 | 0.142 |
| Deferred Taxes | 0 | -9.261 | -1.254 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 3.033 | -72.902 | -27.924 | -18.591 | -10.291 |
| Cash From Operating Activities | -9.672 | -45.568 | -35.92 | -24.568 | -13.277 |
| Cash From Operating Activities | 0.45 | 1.528 | 1.062 | 0.671 | 0.287 |
| Amortization | 0.022 | 3.692 | 2.88 | 1.904 | 0.928 |
| Deferred Taxes | 0 | 0 | 0 | ||
| Non-Cash Items | -11.212 | 24.056 | -9.589 | -6.742 | -2.309 |
| Cash Interest Paid | 0 | 0.024 | 0.024 | 0.021 | 0.013 |
| Changes in Working Capital | -1.965 | -1.942 | -2.349 | -1.81 | -1.892 |
| Cash From Investing Activities | 0 | -4.34 | -3.538 | -2.679 | -1.561 |
| Capital Expenditures | 0 | -4.34 | -3.538 | -2.679 | -1.561 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -0.028 | 35.806 | 35.906 | 36.478 | -0.355 |
| Financing Cash Flow Items | 0 | -0.483 | -0.483 | -0.483 | -0.001 |
| Issuance (Retirement) of Stock, Net | 0 | 37.718 | 37.718 | 37.718 | 0.031 |
| Issuance (Retirement) of Debt, Net | -0.028 | -1.429 | -1.329 | -0.757 | -0.385 |
| Net Change in Cash | -9.7 | -14.102 | -3.552 | 9.231 | -15.193 |
| Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
|---|---|---|---|---|---|---|
| Broadwood Capital, Inc. | Hedge Fund | 34.6606 | 57128042 | 33774345 | 2023-04-03 | LOW |
| AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 10.133 | 16701318 | 9928267 | 2023-04-19 | LOW |
| Pura Vida Investments, LLC | Hedge Fund | 8.9971 | 14829163 | 663000 | 2023-04-14 | MED |
| Norfield Capital, L.L.C. | Corporation | 4.0046 | 6600359 | 6600359 | 2022-11-11 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6448 | 4359202 | 0 | 2023-03-31 | LOW |
| Halle Capital Management LP | Private Equity | 1.8718 | 3085047 | -479681 | 2023-04-24 | |
| Defender Capital LLC | Investment Advisor | 1.4339 | 2363430 | 90500 | 2023-03-31 | LOW |
| Gutfreund (John Peter) | Individual Investor | 1.08 | 1780000 | 1780000 | 2023-04-24 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.8518 | 1403905 | 6978 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6021 | 992454 | 0 | 2023-03-31 | LOW |
| Arno Andrew | Individual Investor | 0.5917 | 975301 | 443252 | 2023-04-24 | LOW |
| Andrews (Ronald Asbury) | Individual Investor | 0.4916 | 583212 | 250000 | 2022-12-01 | |
| Kingsley (Alfred D) | Individual Investor | 0.3174 | 523223 | -10000 | 2023-04-24 | LOW |
| Millennium Management LLC | Hedge Fund | 0.288 | 474711 | -86650 | 2023-03-31 | HIGH |
| Paulsen (Gisela) | Individual Investor | 0.2224 | 366500 | -175000 | 2022-12-01 | |
| ACT Capital Management, L.L.C. | Hedge Fund | 0.2002 | 330000 | 0 | 2022-09-30 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.171 | 281845 | 0 | 2023-03-31 | LOW |
| Ross (Douglas T) | Individual Investor | 0.1973 | 234114 | 63797 | 2022-12-21 | |
| Abaris Investment Management AG | Investment Advisor | 0.1311 | 216000 | -69000 | 2022-10-31 | LOW |
| Penbrook Management, LLC | Investment Advisor | 0.126 | 207675 | 0 | 2023-03-31 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com Group530K+
Obchodníci
87K+
Aktívni klienti za mesia
$46M+
Mesačný objem investícií
$31M+
Výbery každý mesiac
Obchodná kalkulačka
Vypočítajte si svoj hypotetický zisk a stratu, ak ste otvorili obchod s CFD v určitý deň (vyberte dátum) a uzavreli v iný dátum (vyberte dátum).
Obchodná provízia
0
- 1:1
Leverage (pákový efekt)
1:1
- 20
- 100
- 500
- 1000
- 10000
Investície
Veľkosť obchodu (pákový efekt x investície):
Otvorenie
Zatvorenie
Krátke Dlhé
OncoCyte Corporation Company profile
O spoločnosti OncoCyte Corporation
Oncocyte Corporation je spoločnosť zaoberajúca sa molekulárnou diagnostikou. Spoločnosť sa zaoberá vývojom a komercializáciou laboratórne vyvinutých testov (LDT), ktoré slúžia na uspokojenie neuspokojených medicínskych potrieb v celom spektre starostlivosti o pacientov s rakovinou. Testy LTD poskytujú lekárom a pacientom užitočné informácie na optimalizáciu rozhodnutí o liečbe vrátane výberu imunoterapie. Spoločnosť sa zameriava na vývoj neinvazívneho potvrdzujúceho krvného testu na rakovinu pľúc s názvom DetermaDx. DetermaDx je test na predpovedanie rizika recidívy rakoviny u pacienta po operácii a jeho odpovede na chemoterapiu pri včasnom štádiu rakoviny pľúc. Jej vývojový rad zahŕňa TheraSure CNI Monitor, čo je krvný test na monitorovanie imunoterapie, a TheraSure Transplant Monitor, test na monitorovanie transplantácie solídnych orgánov. Jej ďalšie produkty DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq a Imfinzi.
| Industry: | Bio Therapeutic Drugs |
15 Cushing
IRVINE
CALIFORNIA 92618
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 530 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com